RESUMEN
AIM: To conduct a review of "interferon related pericarditis". METHODS: We searched MEDLINE, EMBASE, Cinahl, and the Cochrane Database from the earliest available date through September 2016. A search strategy using the Medical Subject Headings and text keywords "interferon" and "pericarditis" were used. RESULTS: Nine case reports were eligible for the present study. Six of 8 cases were women and the mean age was 43.8 ± 13.8 years with chronic hepatitis C in 6 cases, malignant melanoma in 2 cases and chronic myelogenous leukemia in 1 case. The patients complained of chest pain in 6 cases, dyspnea in 5 cases and edema in 2 cases. Pericardial friction rub was heard in 3 of 9 cases. Congestive heart failure occurred in 3 of 9 cases. Two mechanisms for pericarditis were demonstrated, one is autoimmune included lupus like syndrome in 2 cases and the other is cardio toxicity in 4 cases. Treatment of interferon related pericarditis is discontinuation of Interferon treatment. Four of 9 cases were treated with prednisone and 4 with nonsteroidal anti-inflammatory drugs. CONCLUSION: Interferon related pericarditis still remains uncertain. Treatment of interferon related pericarditis rests mainly on early recognition and drug discontinuation. Interferon related pericarditis was treated with steroid and/or nonsteroidal anti-inflammatory drugs.
RESUMEN
BACKGROUND/PURPOSE: Portal vein ligation (PVL) has been used clinically to decrease the amount of liver before surgical resection, consequently, minimizing postoperative dysfunction in the remaining hypertrophied liver lobes. To date, few reports in the literature have demonstrated the regenerative capacity of unaffected lobes following PVL plus hepatic artery ligation (HAL). This study was conducted in rats to determine a safe and efficacious method of PVL plus HAL, focusing on liver function, the MIB-5 labeling index, and the ratio of the weight of the nonligated lobes to the body weight. METHODS: Group I rats were subjected to PVL of the left lateral and median branches alone (corresponding to approximately 70% total liver volume). In group II, we performed PVL and HAL of the same branches simultaneously, while in group III, HAL was performed 48 h after PVL. A laparotomy without ligature was performed in the control group. Rats from each group were killed at 24, 48, 72, 96, and 168 h after surgery. Standard serum liver functions were tested. Proliferative activity in the nonligated liver was expressed using the Ki-67 antigen (MIB-5) labeling index. Body and nonligated lobe weights were measured. RESULTS: At 96 h post-surgery, the ratio of the weight of the nonligated lobe to body weight was significantly higher in group III than in group I and group II, and induction of the MIB-5 labeling index showed maximum levels in group III. However, quantitative determination of serum glutamic-oxaloacetate transaminase (GOT) showed peak levels in group II at 24 h after surgery. CONCLUSIONS: From these results, we conclude that the PVL plus HAL heterochronous procedure is safer and more efficacious than PVL only, or simultaneous PVL plus HAL. A better knowledge of the events following such heterochronous ligation should improve the clinical outcome of hepatic resection for liver diseases.